“…The most common risk factors for this complication are both patient-related and procedure-related: younger age, female gender, prior ERCP-induced pancreatitis, sphincter of Oddi dysfunction, pancreas divisum, difficulty of cannulation, biliary sphincterotomy or pancreatic opacification [3]. Although some randomized clinical trials (RCTs) have shown a potential benefit of gabexate mesilate and somatostatin in preventing post-ERCP pancreatitis, there are few data to recommend the use of these drugs; moreover, they require continuous infusion and are quite expensive [4,5].…”